(Reuters) – A top executive at Baxalta Inc , which was approached with a takeover offer from Shire PLC, said on Wednesday the company did not plan to rush into doing a defensive deal to try to fend off its unwanted suitor.
Chief Financial Officer Bob Hombach said during a presentation webcast from the Morgan Stanley Global Healthcare conference that the company was still interested in doing deals that made sense, but that it would not change its strategy “just because somebody knocked on our door on day 1.”
Shire approached Baxalta shortly after it was spun off from Baxter International into a standalone public company. Baxalta has so far rejected the offer.
Baxalta shares closed up 1 cent at $37.07 on the New York Stock Exchange. (Reporting by Caroline Humer; Editing by Meredith Mazzilli)
Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.
Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.
The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).